Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glipizide
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Glipizide is a second-generation sulfonylurea oral hypoglycemic agent used to treat type 2 diabetes mellitus. It works by stimulating pancreatic beta cells to release insulin and increasing tissue sensitivity to insulin, thereby lowering blood glucose levels. It is indicated for use in adults with type 2 diabetes, typically as an adjunct to diet and exercise, and may be used in combination with other antidiabetic agents. The drug is not effective for type 1 diabetes or diabetic ketoacidosis. Compared to first-generation sulfonylureas, glipizide has a more rapid onset of action and shorter half-life, reducing the risk of prolonged hypoglycemia[1][2][3][4][5][7].
- Brand names
- GlucotrolGlucotrol XLMinodiabMindiabMelizideGlibeneseDipazide
- Other names
- GlydiazinamideGlucozideGlupizideNapizideSucrazideGlibetinGlidiabGlucolipGlupitelMinidabAldiabDigrinGlicanGlipidGlydeOzidiaGluco-RiteGlipizidaGlipizidum
02
Targets
KCNJ11 (Atp-sensitive inward rectifier potassium channel 11)SUR1 (Sulfonylurea receptor 1)
Beyond the preview
Go deeper on glipizide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glipizide.